MARC ayrıntıları
| 000 -LEADER |
|---|
| fixed length control field |
03662nam a2200277 i 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
820623s2006 nyua o 000 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780120103423 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
BAUN |
| Language of cataloging |
eng |
| Transcribing agency |
BAUN |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
BAUN_MERKEZ |
| 050 04 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
QY90 |
| Item number |
.M35 2006 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Advances in clinical chemistry / |
| Statement of responsibility, etc |
edited by Gregory S. Makowski. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
New York : |
| Name of producer, publisher, distributor, manufacturer |
Academic Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2006. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xi, 336 pages : |
| Other physical details |
illustrations, diagrams ; |
| Dimensions |
23 cm. |
| 336 ## - CONTENT TYPE |
|---|
| Content Type Term |
text |
| Content Type Code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media Type Term |
unmediated |
| Media Type Code |
unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier Type Term |
volume |
| Carrier Type Code |
volume |
| Source |
rdacarrier |
| 490 0# - SERIES STATEMENT |
|---|
| Series statement |
Advances in clinical chemistry ; |
| Volume number/sequential designation |
42 |
| 505 00 - FORMATTED CONTENTS NOTE |
|---|
| Title |
Contents |
| -- |
-- Contributors |
| -- |
-- Preface |
| -- |
-- Chapter 1: Tumor Markers in Detection of Lung Cancer |
| -- |
-- 1. Abstract |
| -- |
-- 2. Introduction |
| -- |
-- 3. Blood/Serum Tumor Markers in the Detection of Lung Cancers |
| -- |
-- 4. Role of Serum Tumor Markers in the Detection of Lung Cancers |
| -- |
-- 5. Role of Other Serum Markers in the Detection of Lung Cancers |
| -- |
-- 6. Role of a Tumor Marker Panel in Improving the Detection of Lung Cancers |
| -- |
-- 7. Value of Less Frequently Used Markers in the Diagnosis of Lung Cancers |
| -- |
-- 8. Summary and Conclusions |
| -- |
-- References |
| -- |
-- Chapter 2: Advances in Serum Protein Electrophoresis |
| -- |
-- 1. Abstract |
| -- |
-- 2. Introduction |
| -- |
-- 3. Technique |
| -- |
-- 4. Instruments |
| -- |
-- 5. Precision |
| -- |
-- 6. Comparison with Gel-Based Techniques |
| -- |
-- 7. Reference Intervals |
| -- |
-- 8. Electrophoretic Patterns |
| -- |
-- 9. Online Processing of Digital Absorbance Data |
| -- |
-- 10. Detection of Monoclonal Proteins |
| -- |
-- 11. Typing of Monoclonal Proteins |
| -- |
-- 12. Urine and Body Fluid Analysis |
| -- |
-- 13. Quality Control |
| -- |
-- 14. Interferences |
| -- |
-- 15. "Open" Capillary Electrophoresis Systems |
| -- |
-- 16. Conclusions |
| -- |
-- Acknowledgment |
| -- |
-- References |
| -- |
-- Chapter 3: Aspirin Resistance: A. Review Of Diagnostic. Methodology, Mechanisms, and Clinical Utility |
| -- |
-- 1. Abstract |
| -- |
-- 2. Introduction |
| -- |
-- 3. Aspirin: Mechanism of Action |
| -- |
-- 4. Methods to Detect Aspirin Resistance |
| -- |
-- 5. Aspirin Resistance Associated with Adverse Outcomes |
| -- |
-- 6. Mechanisms of Aspirin Resistance |
| -- |
-- 7. Aspirin Resistance Associated with Cardiovascular and Cerebrovascular Disease |
| -- |
-- 8. Summary and Recommendations |
| -- |
-- References |
| -- |
-- Chapter 4: Vitreous Fluid Biomarkers |
| -- |
-- 1. Abstract |
| -- |
-- 2. Introduction |
| -- |
-- 3. Methods |
| -- |
-- 4. Molecular Biology |
| -- |
-- 5. Ocular Disease and Clinical Significance |
| -- |
-- 6. Conclusions |
| -- |
-- References |
| -- |
-- Chapter 5: Tumor-associated Carbonic Anhydrases and Their Clinical Significance |
| -- |
-- 1. Abstract |
| -- |
-- 2. Carbonic Anhydrases |
| -- |
-- 3. Basic Characteristics of CA IX and CA XII |
| -- |
-- 4. Regulation of CA IX/CA XII Expression |
| -- |
-- 5. Distribution of CA IX/CA XII in Tumors and Their Clinical Usefulness |
| -- |
-- 6. Role of CA IX/CA XII in Tumor Progression |
| -- |
-- 7. CA IX and CA XII as Molecular Targets for Anticancer Therapy |
| -- |
-- 8. Concluding Remarks |
| -- |
-- Acknowledgments |
| -- |
-- References |
| -- |
-- Chapter 6: Mitochondrial Disease: Maintenance of Mitochondrial Genome and Molecular Diagnostics |
| -- |
-- 1. Abstract |
| -- |
-- 2. Introduction |
| -- |
-- 3. Human Mitochondrial DNA |
| -- |
-- 4. Maintenance of Mitochondrial DNA |
| -- |
-- 5. Pathogenesis of Mitochondrial DNA Mutation |
| -- |
-- 6. Tests of Mitochondrial DNA |
| -- |
-- 7. Mitochondrial DNA in Common Disease |
| -- |
-- 8. Nuclear DNA Mutations and Mitochondrial Disease |
| -- |
-- 9. Perspectives |
| -- |
-- 10. Conclusion and Remarks |
| -- |
-- Acknowledgments |
| -- |
-- References |
| -- |
-- Chapter 7: Microfluidic Enzyme-Linked Immunosorbent Assay Technology |
| -- |
-- 1. Abstract |
| -- |
-- 2. Introduction |
| -- |
-- 3. Key Issues in Develo. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Clinical chemistry. |
|
|---|
| Topical term or geographic name as entry element |
Biochemistry. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Makowski, Gregory S. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
ebrary, Inc. |
| 900 ## - EQUIVALENCE OR CROSS-REFERENCE-PERSONAL NAME [LOCAL, CANADA] |
|---|
| Personal Name |
19533 |
|
|---|
| Numeration |
Satın |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Kitap |
-baunlogo.png?alt=media&token=2b1f50b7-298a-48ee-a2b1-6fcf8e70b387)
-Facebook-2024.png?alt=media&token=2fcc0655-0091-431c-8ee0-059464d6eda1){kind=small}
-Instagram-2024.png?alt=media&token=a143a92a-6f9d-45a7-9ba2-9cc62f92e772){kind=small}